Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia

Next Previous
Trial Profile

An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obecabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine; Inotuzumab ozogamicin
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ALLCAR; FELIX
  • Sponsors Arix Bioscience; Autolus

Most Recent Events

  • 07 Dec 2024 According to Adaptive Biotechnologies Corporation media release, company presented at the 66th Annual Meeting of the American Society of Hematology (ASH), taking place December 6-10 in San Diego.
  • 27 Nov 2024 According to MD Anderson Cancer Center Media Release, data from the study were presented in the New England Journal of Medicine.
  • 27 Nov 2024 Results presented in the MD Anderson Cancer Center Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top